P209: Introduction to Personalized ADR History Notification System in Korea for Preventing Re-exposure to Culprit Drugs
Poster Presenter
Bonggi Kim
Director
Korea Institute of Drug Safety and Risk Management Korea, Republic of
Objectives
Patients with serious adverse drug reactions (ADRs) are at high risk of recurrence when re-exposed to the same or similar drugs. This study introduces Korea’s personalized ADR history notification system and evaluates its effectiveness in preventing ADR recurrence.
Method
To evaluate the system’s effectiveness, all patients and alert records registered in the ADR history notification system from December 17, 2020, to June 30, 2025, were analyzed. Key outcomes included overall prescription patterns and re-prescription rates of culprit drugs.
Results
Korea’s personalized ADR history notification system provides prescribing and dispensing alerts to physicians and pharmacists based on individual patients’ ADR history, including culprit drugs. The system is linked to the national ADR Relief Program, which compensates patients experiencing serious ADRs resulting in death, disability, or hospitalization. Each claim is assessed for causality between the suspected drug and the ADR through expert consultation and committee review. For confirmed cases, personalized ADR history information is generated with patient consent and integrated into the system for clinical use.
The system initially launched on December 17, 2020, covering high-frequency culprit drugs: allopurinol, carbamazepine, oxcarbamazepine, phenytoin, and lamotrigine. In 2021, additional drugs including acetaminophen, cefaclor, and contrast media were incorporated. Coverage was progressively expanded to anti-tuberculosis agents in 2022, antibiotics in 2023, and by July 2024, all registered drug ingredients were included. To prevent ADR recurrence from similar drugs, alerts were also configured for isomers, prodrugs, and related compounds.
From December 17, 2020, to June 30, 2025, a total of 391 ADR history records across 131 drug ingredients were registered. During this period, 24,657 prescriptions for registered patients were evaluated, and the re-prescription rate of culprit drugs was 0.008%, demonstrating the system’s effectiveness in preventing re-exposure to high-risk medications.
Conclusion
The personalized ADR history notification system in Korea has been shown to effectively prevent re-prescription of the same drugs and reduce the recurrence of serious ADRs. By providing real-time alerts to physicians and pharmacists, the system enhances patient safety and supports clinical decision-making. To further maximize the system’s utility and adoption, ongoing promotion, education for healthcare providers, and integration into routine prescribing and dispensing workflows are recommended. Continuous evaluation and refinement will support sustained improvements in patient safety, minimizing preventable serious ADRs and contributing to safer clinical care in Korea.
